Classifications

• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
  • C12P7/00—Preparation of oxygen-containing organic compounds
  • C12P7/02—Preparation of oxygen-containing organic compounds containing a hydroxy group
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
  • C12P13/00—Preparation of nitrogen-containing organic compounds
  • C12P13/001—Amines; Imines

Definitions

• the present invention relates to a novel process for the preparation of (1S,2S)-1-halo-2-hydroxy-3-(protected)amino-4-substituted butanes by stereoselective reduction of the corresponding oxo compounds.
• the substituted butanes produced in accordance with the process of the inventions are precursors of hydroxyethylamine isostere sub-units present in many molecules therapeutically useful as inhibitors of angiotensin converting enzyme, renin and HIV-protease.
• the present invention is directed to a novel stereoselective process for the preparation of (1S,2S)-1-halo-2-hydroxy-3-(protected)amino-4-substituted butanes by the reduction of the corresponding keto group containing compounds by certain species of Rhodococcus and Brevibacterium.
• the products are obtained in high yield and in excellent diastereomeric purity.
• Hal is a halogen, preferably chlorine
• R is selected from the group consisting of alkyl, substituted alkyl, aryl and substituted aryl and R 1 is a protecting group for the amino function.
• the substituted butanes represented by formula I are useful as intermediates in the synthesis of molecules that are inhibitors of ACE, renin and HIV proteases.
• the activity of such molecules against HIV proteases makes them very valuable in the treatment of retroviral infections such as AIDS.
• Such compounds and their use are disclosed, for example, in U.S. Pat. No. 5,849,911, the disclosure of which is incorporated herein by reference.
• 5,849,911 is [3S-(3R*,8R*,9R*,12R*)]-3,12-Bis(1,1-dimethylethyl)-8-hydroxy-4,11-dioxo-9-(phenylmethyl)-6 ⁇ [4-(2-pyridinyl)phenyl]methyl ⁇ -2,3,6,10,13-pentaazaretetradecanedioic acid dimethyl ester.
• This compound may be directly synthesized from the (1S,2S)-1-halo-2-hydroxy-3-(protected)amino-4-substituted butanes represented by formula I.
• the fact that the process of the present invention produces a very high yield of the trans (1S,2S) enantiomer of the substituted butanes represented by formula I makes it very important to the ultimate efficiency of the synthesis of the therapeutic compound described above.
• alkyl refers to optionally substituted straight- or branched-chain saturated hydrocarbon groups having from 1 to 7 carbon atoms, preferably from 1 to 4 carbon atoms.
• lower alkyl refers to optionally substituted alkyl groups having from 1 to 4 carbon atoms.
• substituted alkyl refers to an alkyl group substituted by, for example, one to four substituents, such as, halo, trifluoromethyl, trifluoromethoxy, hydroxy, alkoxy, cycloalkyoxy, heterocylooxy, oxo, alkanoyl, aryl, aryloxy, aralkyl, alkanoyloxy, amino, alkylamino, arylamino, aralkylamino, cycloalkylamino, heterocycloamino and disubstituted amino.
• substituents such as, halo, trifluoromethyl, trifluoromethoxy, hydroxy, alkoxy, cycloalkyoxy, heterocylooxy, oxo, alkanoyl, aryl, aryloxy, aralkyl, alkanoyloxy, amino, alkylamino, arylamino, aralkylamino, cycloalkyla
• aryl refers to monocyclic or bicyclic aromatic hydrocarbon groups having from 6 to 12 carbon atoms in the ring portion, for example, phenyl, naphthyl, biphenyl and diphenyl groups, each of which may be substituted.
• aralkyl refers to an aryl group bonded to a larger entity through an alkyl group, for example, a benzyl radical.
• substituted aryl refers to an aryl group substituted by, for example, one to four substituents such as alkyl; substituted alkyl, halo, trifluoromethyl, trifluoromethoxy, hydroxy, alkoxy, cycloalkyloxy, heterocyclooxy, alkanoyl, alkanoyloxy, amino, alkylamino, dialkylamino, aralkylamino, cycloalkylamino, heterocycloamino, alkanoylamino, thiol, alkylthio, cycloalkylthio, heterocyclothio, ureido, nitro, cyano, carboxy, carboxylalkyl, carbamyl, alkoxycarbonyl, alkylthiono, arylthiono, alkysulfonyl, sulfonamido, aryloxy and the like.
• the substituent may be further substituted by
• halogen refers to chlorine, bromine, fluorine and iodine, with chlorine being preferred.
• protecting group on the amino function refers to an art-recognized group of moieties that can be attached to an amino group to keep it from being involved in reactions taking place elsewhere on the molecule to which it is attached. Preferred among such groups is t-butoxycarbonyl (BOC), but art-recognized amino function protecting groups, generally alkoxycarbonyl groups such as benzyloxycarbonyl, can be used as well.
• BOC t-butoxycarbonyl
• alkoxycarbonyl groups such as benzyloxycarbonyl
• R and R 1 are as defined above and R 2 is hydrogen or nitro and may be substituted in the ortho or para position on the phenyl ring is reacted with a sulfur ylide, i.e. a compound containing a function represented by the formula
• R and R 1 are as defined above and R 3 and R 4 are selected from the group consisting of alkyl, substituted alkyl and aryl.
• the keto ylide compound represented by the above formula is then converted to the keto group-containing compounds represented by formula II by reaction with a source of chloride, preferably a basic source of chloride, most preferably lithium chloride, and an organic acid, for example, methanesulfonic acid.
• the (1S,2S)-1-halo-2-hydroxy-3-(protected)amino-4-substituted butanes represented by formula I above are important intermediates of in the synthesis of molecules that are inhibitors of ACE, renin and HIV proteases. The activity of such molecules against HIV proteases makes them very valuable in the treatment of retroviral infections such as AIDS.
• the (1S,2S)-1-halo-2-hydroxy-3-(protected)amino-4-substituted butanes represented by formula I are treated with a suitable base to convert them to the corresponding epoxides represented by the formula shown below
• the epoxide compounds represented by formula shown above are intermediates that can be converted to the important AIDS compound [3S-(3R*,8R*,9R*,12R*)]-3,12-Bis(1,1-dimethylethyl)-8-hydroxy-4,11 -dioxo-9-(phenylmethyl)-6 ⁇ [4-(2-pyridinyl)phenyl]methyl ⁇ -2,3,6,10,13-pentaazaretetradecanedioic acid dimethyl ester as disclosed in U.S. Pat. No. 5,849,911, the disclosure of which is incorporated herein by reference.
• the stereoselective reduction of the (1S)-1-halo-2-oxo-3-(protected)amino-4-substituted butanes represented by formula II above to form the (1S,2S)-1-halo-2-hydroxy-3-(protected)amino-4-substituted butanes represented by formula I is carried out in accordance with the present invention by reaction with an oxidoreductase enzyme, or preferably, a microorganism that supplies an oxidoreductase enzyme capable of catalyzing the enzymatic reduction of the ketones represented by formula II.
• the cells of the microorganism may be in the form of intact wet cells or dried cells such as lyophilized, spray-dried or heat-dried cells, or in the form of treated cell material such as ruptured cell or cell extracts. While a large and varied number of microorganisms are known to supply some form of oxidoreductase, it has been found in accordance with the present invention that only selected species of Rhodococcus and Brevibacterium catalyze the reduction of the compound represented by formula II to form the desired (1S,2S)-1-halo-2-hydroxy-3-(protected)amino-4-substituted butanes in high quantitative and enantiomeric yield.
• Rhodococcus erythropolis ATCC 4277 Rhodococcus erythropolis DSM 6971 and Rhodococcus sp. ATCC 21227, Rhodococcus erythropolis ATCC 27854 and Brevibacterium sp. ATCC19653.
• ATCC refers to the accession number of the depository for the particular organism, i.e. the American Type Culture Collection, 12301 Parklawn Drive, Rockville, Md. 20852.
• DSM refers to the German Collection of Microorganisms and Cell Cultures, Branschweig, Germany.
• the enzymatic reduction method of the present invention may be carried out subsequent to the fermentation of the microorganism employed, i.e. as a two-stage fermentation and reduction, or concurrently therewith, i.e. as a single-stage or in situ fermentation and reduction.
• the microorganism may be grown in an appropriate medium, especially one containing nitrogen and carbon sources, until sufficient growth is realized and then a compound selected from those compounds represented by formula II is added thereto.
• the enzymatic reduction is thereafter continued until virtually complete conversion of the compound represented by formula II is attained.
• the microorganism is initially grown in a suitable medium as described above until it exhibits a predetermined level of enzymatic activity at which point the cells are harvested by conventional separation techniques and microbial cell suspensions prepared therefrom containing appropriate buffering agents and the like.
• Suitable buffering agents include phosphate buffers, particularly potassium phosphate buffer, tris-HCl, sodium acetate and the like. Water may also be used to prepare suspensions of microbial cells.
• the compound represented by formula II is then added thereto and the enzymatic reduction continued until the conversion is virtually complete.
• the appropriate growth medium will include, as previously stated, sources of carbon and nitrogen and trace elements. Inducers may be added as well.
• inducer means any compound initiating or enhancing the desired enzymatic, i.e. oxidoreductase, activity within the cell to produce the desired product.
• the (1S)-1-halo-2-oxo-3-(protected)amino-4-substituted butanes represented by formula II would be considered an inducer, particularly when added in small quantities during the growth of the microorganism.
• Suitable carbon sources for the medium may include sugars, such as maltose, lactose, glucose, fructose, glycerol, sorbitol, sucrose, starch, mannitol, propylene glycol and the like, organic acids and their salts such as sodium acetate, sodium citrate and the like, amino acids and their salts, such as sodium glutamate and the like, and alcohols, such as ethanol, propanol and the like.
• sugars such as maltose, lactose, glucose, fructose, glycerol, sorbitol, sucrose, starch, mannitol, propylene glycol and the like
• organic acids and their salts such as sodium acetate, sodium citrate and the like
• amino acids and their salts such as sodium glutamate and the like
• alcohols such as ethanol, propanol and the like.
• Suitable nitrogen sources may include N-Z amine A, corn steep liquor, soy bean meal, beef extracts, yeast extracts, molasses, baker's yeast, tryptone, nutrisoy, peptone, yeastamin, sodium nitrate, ammonium sulfate and the like.
• Suitable trace elements may include phosphates, and magnesium, manganese, calcium, cobalt, nickel, iron, sodium and potassium salts.
• the appropriate media utilized in accordance with the present invention may include a plurality of constituents selected from any of these categories. Representative preferred media include without intended limitation aqueous media containing the following, in weight percent: Ingredient Weight Percent No.
• the pH given above for the media is post-sterilization. Before sterilization, the pH is preferably adjusted to from about 6 to 8, most preferably about pH 6.5. The media are then sterilized, for example, by heating at a temperature of about 121° C. for 30 minutes. Following sterilization, the media are adjusted to pH 6.5 to 7.5, most preferably about pH 7.0. During microbial growth and the reduction process, the pH is maintained at between about 4.0 and 9.0, preferably between about pH 6.0 and 8.0. An appropriate base or acidic salt from among the constituents named above can conveniently be utilized for adjustment of the pH.
• the temperature of the reaction mixture is a measure of the heat energy available for the reduction process, and for this reason, a suitable temperature should be maintained to ensure that there is sufficient energy available for the process to go to completion.
• a suitable temperature range for the process of the invention is in the range of from about 15° C. to about 60° C., preferably from about 25° C. to about 40° C.
• Pressure is not known to be critical for the practice of the process of the invention and for convenience about atmospheric pressure is typically maintained.
• the process of the present invention is preferably carried out under aerobic conditions. Agitation and aeration of the reaction mixture is also beneficial to the subject process in that is affects the amount of oxygen available for the biotransformation.
• the process is advantageously carried out, for example, in shake-flask cultures or fermentor tanks during the growth of the microorganisms in a single-stage or two-stage process as described above. Agitation in the range of from about 50 to 1000 RPM is preferred, with from about 50 to 500 RPM being most preferred. Aeration of from about 0.1 to 10 volumes of air per volume of media per minute (v/Vt.) is preferred, with aeration of about 5 volumes per volume of media per minute being particularly preferred.
• Complete conversion of the compound represented by formula II may require, for example, from about 4 to 48 hours, typically from about 4 to 24 hours, measured from the time of addition of the compound represented by formula II to the media. It is preferred that the media be aqueous based, although an organic liquid or a miscible or immiscible, i.e. biphasic, organic/aqueous liquid mixture may be utilized as well.
• the stereoselective enzymatic reduction process of the present invention may be carried out using a co-factor such as nicotinamide adenine dinucleotide (NADH), especially when an isolated enzyme would be utilized.
• NADH for example, may thereafter be regenerated and reused.
• a further enzyme that regenerates the NADH in situ may be employed such as formate dehydrogenase or glucose dehydrogenase.
• Suitable hydrogen donors include molecular hydrogen, a formate (e.g. an alkali metal or ammonium formate), glucose, a hypophosphite or an electrochemical reduction in the presence of a viologen, for example methyl viologen.
• the compound of formula II it is also possible to regenerate NADH without further enzymes using, for example, ethanol or formate. It is further preferred to add the compound of formula II to the reaction media so that it is from about 0.2% to about 5% by weight, based on the combined weight of starting compound and media.
• the inoculum of microorganism relative to the amount of starting material is sufficient to provide for the enzymatic reduction of the compound represented by formula II with the times described above, generally from about 5 wt. % to about 30 wt. % cells concentration.
• the product of the reduction process of the present invention i.e. the compounds represented by formula I may be recovered by any suitable methods for isolation and/or purification, e.g. methodologies such as extraction, distillation, crystallization, column chromatography and the like.
• Rhodococcus erythropolis ATCC 4277 cells (1 mL) was inoculated into 100 mL of Medium 1 as noted above in a 500 mL flask and incubated at 28° C. and 200 RPM on a shaker for 22 hours.
• the pH of 50 cells broth was adjusted to pH 7.0 with 1 M potassium phosphate buffer.
• Glucose was added to the cell broth at 25 mg/mL and 50 mg.
• (1S)-[N-(1-benzyl-2-oxo-3-chloro)propyl]carbamic acid t-butyl ester (the substrate) was added thereto.
• the biotransformations (reductions) were carried out at 28° C. and 200 RPM on a shaker.
• reaction mixtures were quenched with two volumes of a 60:40 mixture of t-butyl methyl ether and toluene, and the separated organic phase was filtered through a 0.2 micron filter and collected. Two mL of the organic phase was evaporated to dryness under a stream of nitrogen and the residue taken up with 1 mL of acetonitrile, filtered and analyzed by HPLC for (1S,2S)-[N-(1-benzyl-2-hydroxy-3-chloro)propyl]carbamic acid t-butyl ester (the product). The results are summarized in Table 1 below.
• Example 2 The substrate and the product for this Example were as described in Example 1.
• Cells of Rhodococcus erythropolis ATCC 4277 and Rhodococcus erythropolis DSM 6971 (1 mL) were individually inoculated into 100 mL portions of Medium 1 as noted above in a 500 mL flask and incubated at 25° C. and 280 RPM on a shaker for 48 hours.
• One hundred mL of each culture was innoculated into 15 mL of Medium 1 combined in a fermentor. Growth in the fermentor was carried out at 25° C., 15 LPM (liters per minute) aeration and 500 RPM agitation for 36 hours.
• Cells were harvested from the fermentor and used for the enzymatic conversion (biotransformation) of (1S)-[N-(1-benzyl-2-oxo-3-chloro)propyl]carbamic acid t-butyl ester (the substrate) to (1S,2S)-[N-(1-benzyl-2-hydroxy-3-chloro)propyl]carbamic acid t-butyl ester (the product).
• Cell suspensions were prepared by suspending the cells, 20 grams in 100 mL of 64 mM potassium phosphate buffer, pH 7.0. To each suspension was added 25 mg/mL of glucose and a predetermined concentration of substrate. The biotransformation of the substrate to the product was carried out at 28° C.
• the substrate for this process and the product were as in the previous Examples.
• Cells of Rhodococcus erythropolis ATCC 4277 were grown on Medium 1 as described above.
• Cells (150 grams) were suspended in 100 mL of potassium phosphate buffer, pH 7.0.
• the cell suspensions were disintegrated at 4° C. by use of a microfluidizer at 13,000 psi pressure.
• the disintegrated cell suspension was centrifuged at 12,000 RPM for 30 minutes.
• the clear supernant (“cell extracts”) was utilized for the biotransformation of the substrate to the product.

Landscapes

• Organic Chemistry (AREA)
• Chemical & Material Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Zoology (AREA)
• Engineering & Computer Science (AREA)
• Wood Science & Technology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Genetics & Genomics (AREA)
• General Chemical & Material Sciences (AREA)
• Biotechnology (AREA)
• Microbiology (AREA)
• Health & Medical Sciences (AREA)
• Biochemistry (AREA)
• Bioinformatics & Cheminformatics (AREA)
• General Engineering & Computer Science (AREA)
• General Health & Medical Sciences (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Preparation Of Compounds By Using Micro-Organisms (AREA)
• Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
• Epoxy Compounds (AREA)

Priority Applications (2)

Applications Claiming Priority (3)

Related Child Applications (1)

Publications (1)

Family

ID=26919835

Family Applications (2)

Family Applications After (1)

Country Status (18)

Families Citing this family (12)

Family Cites Families (8)

• 2001
  • 2001-07-20 US US09/909,684 patent/US20020042124A1/en not_active Abandoned
  • 2001-07-20 AT AT01959109T patent/ATE431422T1/de not_active IP Right Cessation
  • 2001-07-20 WO PCT/US2001/023113 patent/WO2002014528A1/en active IP Right Grant
  • 2001-07-20 AU AU8069801A patent/AU8069801A/xx active Pending
  • 2001-07-20 IL IL15437601A patent/IL154376A0/xx unknown
  • 2001-07-20 PL PL01366098A patent/PL366098A1/xx not_active Application Discontinuation
  • 2001-07-20 CN CNB01814196XA patent/CN100335643C/zh not_active Expired - Lifetime
  • 2001-07-20 CZ CZ20030758A patent/CZ303884B6/cs not_active IP Right Cessation
  • 2001-07-20 MX MXPA03001312A patent/MXPA03001312A/es active IP Right Grant
  • 2001-07-20 EP EP01959109A patent/EP1309714B1/de not_active Expired - Lifetime
  • 2001-07-20 JP JP2002519654A patent/JP3843255B2/ja not_active Expired - Lifetime
  • 2001-07-20 ES ES01959109T patent/ES2325309T3/es not_active Expired - Lifetime
  • 2001-07-20 CA CA002417086A patent/CA2417086A1/en not_active Abandoned
  • 2001-07-20 HU HU0300873A patent/HU229338B1/hu unknown
  • 2001-07-20 BR BRPI0113236-9A patent/BR0113236B1/pt not_active IP Right Cessation
  • 2001-07-20 AU AU2001280698A patent/AU2001280698B2/en not_active Expired
  • 2001-07-20 KR KR10-2003-7002257A patent/KR20040031674A/ko not_active Application Discontinuation
  • 2001-07-20 DE DE60138712T patent/DE60138712D1/de not_active Expired - Lifetime
  • 2001-08-16 TW TW090120123A patent/TWI287579B/zh not_active IP Right Cessation
• 2003
  • 2003-09-12 US US10/661,893 patent/US7083973B2/en not_active Expired - Lifetime

Also Published As

Similar Documents

Legal Events